Stockholm, September 28, 2022 – Umecrine Cognition AB today announced results showing that the company’s clinical drug candidate golexanolone largely eliminated fatigue in a preclinical disease…
STOCKHOLM – September 14, 2022. Umecrine Cognition today announces that the company has secured funding of SEK 41 million for the start of a Phase 2 study of its drug candidate golexanolone in…
SOLNA – August 10, 2022. Umecrine Cognition AB today announces that its Board of Directors has appointed Anders Karlsson as new CEO. He succeeds Magnus Doverskog, who will move on to a position as…
The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the extraordinary general meeting at 10:00 a.m. on Wednesday 10 August 2022. The meeting will be…
STOCKHOLM – May 19, 2022. Umecrine Cognition AB today announces that the company has submitted a clinical trial application (CTA) for a Phase 2 study of golexanolone in patients with primary…
The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the annual general meeting at 10:00 a.m. on Friday 17 June 2022 at Setterwalls Advokatbyrå’s…
STOCKHOLM – March 14, 2022. Umecrine Cognition AB today announces that the company has completed a pre-IND meeting with the U.S. Food and Drug Administration (FDA). Based on a recent interaction…
STOCKHOLM – February 21, 2022. Umecrine Cognition AB today announces that the company will present positive data from a recently concluded nonclinical study at the 11th International Meeting on…
Stockholm, January 10, 2022 – Umecrine Cognition AB today announced nonclinical results showing that its clinical drug candidate golexanolone exerts a normalizing effect on neuroinflammation in the…